Antiverse, a biotech firm based in Cardiff, Wales, has successfully secured $9.3 million in funding to enhance its innovative drug discovery initiatives. This investment will accelerate the development of its AI-powered platform, which specializes in designing antibody-based therapeutics.
Innovative Drug Discovery
Antiverse’s computational platform is designed to tackle challenging drug targets, particularly G-protein coupled receptors (GPCRs) and ion channels. The company claims that its technology can streamline the process, moving from target identification to a functional antibody in as little as six months. This efficiency positions Antiverse as a significant player in the rapidly evolving biotech landscape.
Series A Funding and Backers
The recent Series A funding round was supported by Innovation Investment Capital (IIC), a fund backed by the Cardiff Capital Region (CCR), and the Development Bank of Wales, among other international investors. This financial backing reflects a broader confidence in Antiverse’s potential.
Strategic Partnerships
Founded in 2020 and launching formally in 2022, Antiverse has already established multiple partnerships to leverage its technology. Notably, the firm has a collaboration with Japan’s Nxera Pharma to design antibodies targeting GPCRs. These receptors are crucial in cellular communication and pose a challenge due to their complexity and instability.
Collaborations with Pharma Giants
In addition to its partnership with Nxera Pharma, Antiverse has entered alliances with two undisclosed pharmaceutical companies. One collaboration involves designing antibodies targeting parts of transmembrane proteins, while the other focuses on T-cell receptors (TCRs). Furthermore, the company is collaborating with GlobalBio on developing anti-PD-1 antibodies, which are currently advancing through preclinical development.
Growth and Validation
Murat Tunaboylu, Antiverse’s chief executive and co-founder, emphasized that this investment is not merely financial support; it serves as validation for the company’s approach to tackling difficult targets. Tunaboylu asserts that the ability to effectively target GPCRs and ion channels demonstrates the potential of AI in drug discovery.
Future Prospects
The funding will be instrumental in scaling Antiverse’s platform and expanding its team. The company plans to create five new positions, building on its current workforce of 19. The investment also lays the groundwork for a future Series B funding round, enabling further advancements in their technology and partnerships.
Conclusion
Antiverse stands at the forefront of a transformative era in biotech, where AI plays a critical role in antibody discovery. With robust funding and strategic partnerships, the company is well-positioned to redefine therapeutic development. As Antiverse continues to innovate, it sets a powerful example of how technology can revolutionize the life sciences.
- Antiverse raised $9.3 million to enhance AI-driven antibody development.
- The company’s platform can create functional antibodies in just six months.
- Strategic partnerships with global pharma firms enhance its credibility.
- The funding will support the creation of five new jobs.
- The investment is seen as validation of Antiverse’s innovative approach in drug discovery.
Read more → pharmaphorum.com